Table 1 Naming test characteristics and utility in detecting naming deficits in neurocognitive disorders
From: Naming ability assessment in neurocognitive disorders: a clinician’s perspective
Stand-alone dysnomia tests | Dysnomia tests embedded in global cognitive examination tools | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
BNT | ANT | Wo-Fi | MINT 32 items | GBT/ GFT/ GNT | NAB Naming subtest | TDQ-30 | VNT | ACE-III Naming subtest | MoCA Naming subtest | |
Items | 60 | 50 | 50 | 32 | 30 | 31 | 30 | 55 | 16 | 3 |
Stimuli type | visual | auditory | auditory | visual | visual | visual | visual | visual | visual | visual |
Time (in minutes) | < 20 | < 20 | < 15 | < 15 | < 15 | < 10 | < 10 | < 10 | < 5 | < 1 |
Average test item frequency | 1.717 | 2.26 | 1.52 | 2 | 2 | – | 1.75 | 1.872 | 2 | 2 |
Assessment parameters | Correctly named items | Correctly named items, tip-of-the tongue extended latency score, reaction time per response | Correctly named items | Correctly named items | Correctly named items | Correctly named items | Correctly named items | Correctly named items | Correctly named items | Correctly named items |
Access | Available for purchase Link | Open Link | Open Link | Open Link | Available for purchase GNT Link GFT Link GBT Link | Available for purchase Link | Open Link | Open Link | Open Link | Open Link |
Language Availability | More languages | English | German | English, Spanish | English | English | French | English | More languages | More languages |
Validation studies | Knesevich JWm et al. 1986 Erdodi La et al. 2018 | Hirsch J et al. 2016 Hirsch J et al. 2021 | Camerer-Waldecker C et al. 2019 | Stasenko A et al. 2019 | Ahmed S et al. 2008 | Sachs B et al. 2016 Durant J et al. 2021 | MacOir J et al. 2021 | Yochim BP et al. 2015 Modore MR et al. 2020 | Calderon C et al. 2021 | Moafmashhadi P et al. 2013 |
Neurocognitive disorders of validation samples | MiND, MaND due to AD, due to vascular brain disease, due to PD, due to Lewy bodies, due to mixed aetiologies | MiND, MaND due to AD, due to vascular brain disease, due to mixed aetiologies | MaND due to AD | MiND, MaND due to AD | MiND | MiND, MaND due to AD, due to PD, due to Lewy bodies | MiND, MaND due to AD | MiND, MaND due to AD, due to vascular brain disease, due to PD, due to mixed aetiologies | MaND due to AD | MaND due to AD, due to vascular brain disease, due to PD, due to FTLD, due to mixed aetiologies |
Sensitivity | 15–41% | 69% | 95% | 75-83% | 78% | 79-80% | 38% | 72-79% | N/A | 41% |
Specificity | 87-95% | 81% | 92% | 70-81% | 87% | 73-78% | 99% | 80-85% | N/A | N/A |